Aggressive malignancy screening in SSc patients may aid in early cancer detection and further study is required to determine whether cancer therapy could improve scleroderma outcomes in this patient population. PubMed, Curr Opin Rheumatol, 2015 Nov;27(6):563–70. (Also see Cancer and Scleroderma)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.